FindTrial
Sign In

pulsENDO treatment

PROCEDURE2 trials

Sponsors

Chinese University of Hong Kong

Conditions

Diabete MellitusMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Syndrome (MetS)T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)T2DM (Type 2 Diabetes Mellitus)

Unknown Phase

Duodenal pulsENDO as an Early Treatment for Type 2 DM
RecruitingNCT07376486
Chinese University of Hong KongDiabete Mellitus, T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
Start: 2026-09-01End: 2032-08-30Target: 40Updated: 2026-09-15
Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease
RecruitingNCT07390422
Chinese University of Hong KongMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Syndrome (MetS), T2DM (Type 2 Diabetes Mellitus)
Start: 2026-09-01End: 2033-08-30Target: 40Updated: 2026-09-15